In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, new
compounds based on a combination of clofibric acid, the active metabolite of clofibrate, and trans-stilbene, chalcone, and
other lipophilic groups were synthesized. They were evaluated for PPARα transactivation activity; all branched derivatives
showed an increase of the transcriptional activity of receptor compared to the linear ones. Noteworthy, stilbene
and benzophenone branched derivatives activated the PPARα better than clofibric acid.